Article: Risedronate

Risedronate
Systematic (IUPAC) name
(1-hydroxy-1-phosphono-2-pyridin-3-yl-ethyl)phosphonic acid
Identifiers
CAS number	105462-24-6
ATC code	M05BA07
PubChem	5245
DrugBank	APRD00410
Chemical data
Formula	C7H11NO7P2
Mol. weight	283.112 g/mol
Pharmacokinetic data
Bioavailability	0.63%
Protein binding	~24%
Metabolism	None
Half life	1.5 hours
Excretion	Renal and fecal
Therapeutic considerations
Pregnancy cat.	B3(AU) C(US)
Legal status	POM(UK) ℞-only(US)
Routes	Oral

Risedronate sodium (Actonel®) is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis, and treat Paget's disease of bone. It is produced and marketed by Proctor and Gamble and Sanofi-Aventis.

Administration

Risedronate is taken orally, usually 5 mg daily or 35 mg weekly. Notably, if risedronate lodges in the esophagus, it can lead to esophageal ulcers. Therefore, it is recommended that risedronate be taken with the body upright, and followed by a glass of water. Moreover, risedronate is poorly absorbed when taken with food, so it is recommended that no food or drink other than water be taken for 2 hours before and 30 minutes after taking risedronate. Risedronate has a faster esophageal transit time and different chemical chain which results in less gastrointestinal side-effects than other drugs in this class. The dosage instructions also show that risedronate can be taken with less water than other drugs in the class.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.